Background and Objectives Reliable biomarkers for autoimmune encephalitis (AE) are limited, and emerging CSF markers are not incorporated into current diagnostic criteria. Prognostic tools remain insufficient, highlighting the need for biomarkers that support both early diagnosis and assessment of disease severity and...
F. Konen, E. Bucak, F. Bachhuber et al.· Neurology(R) neuroimmunology...· 0 citations
It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
M. Einsiedler, S. Sandgren, S. Schaedelin et al.· JAMA Neurology· 0 citations
This review addresses measurement methods (SiMoA, automated platforms), pre-analytics/matrix effects, and central confounders (esp. age, BMI/volume of distribution, renal function, intercurrent events), emphasizing standardization via age- and BMI-corrected reference data using Z-scores or percentiles.
Hernan Inojosa, K. Akgün, L. Masanneck et al.· Fortschritte der Neurologie...· 0 citations
A review of current evidence on established and emerging fluid biomarkers in NMOSD and MOGAD, with emphasis on analytical performance, biological relevance, and clinical utility, and outlines priorities for future research.
S. Mariotto, Á. Cobo-Calvo, M. Khalil et al.· Neurology(R) neuroimmunology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
